A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1018 participants.
Also called NCT05035082
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,018 participants
- Sponsor
- Registry
-
NCT05035082
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05035082. Randomized; no masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2025-06-18 (actual). Results posted on 2026-08-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
- Acronym
- REALYSE
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- oral glucose-lowering medications (commercially available)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05035082- Content hash
1e5031dd29cd7d5a0c37b70bc71f0c7edb8f0bf5bbaa6a07e2664871eb66f1a1